|
WO2020229526A1
|
|
Improved lyophilized formulations involving hyaluronic acid and plasmatic proteins, and uses thereof
|
|
BE1026600A1
|
|
METHODS AND USES TO DETERMINE THE OSTEOGENIC POTENTIAL OF DIFFERENTIATED CELLS IN VITRO
|
|
BE1026595A1
|
|
METHODS OF DIFFERENTIATING MESENCHYMATIC STEM CELLS
|
|
US2020354682A1
|
|
Methods for differentiating mesenchymal stem cells
|
|
CN107592789A
|
|
The storage in vitro of therapeutic cells
|
|
WO2014049063A1
|
|
Formulations involving solvent/detergent-treated plasma (s/d plasma) and uses thereof
|
|
CN103857788A
|
|
Uses of growth and differentiation factor 8 (gdf-8)
|
|
AU2012266241A1
|
|
Markers for impaired bone fracture healing
|
|
EP2297304A1
|
|
Human bone-forming cells in the treatment of conditions and bone diseases associated with immunodeficiency or immunosuppression
|
|
BE1018748A3
|
|
Novel mesenchymal stem cells and osteogenic cells.
|
|
US2010272696A1
|
|
Human Bone-Forming Cells In The Treatment of Inflammatory Rheumatic Diseases
|
|
US2010278788A1
|
|
Osteogenic Differentiation Of Bone Marrow Stem Cells And Mesenchymal Stem Cells Using A Combination Of Growth Factors
|
